EMA Grants First Two PRIME Designations In 2024 To Ultragenyx & Sangamo
Executive Summary
Ultragenyx’s antisense oligonucleotide for treating Angelman syndrome and Sangamo’s gene therapy for Fabry disease are the latest products to make it onto the European Medicines Agency’s priority medicines scheme.